SLC5A2 and chronic kidney disease: Consequently, although SGLT2is provide substantial clinical benefits, and several mechanisms of action have been proposed and validated, the precise molecular and cellular pathways that confer kidney protection remain incompletely defined, particularly in advanced CKD, where SGLT2 expression is markedly reduced [14,15].